About Us
Our Story
Goldenrod is advancing the small molecule, 11h, that was invented by Dr. Corey Hopkins at the University of Nebraska Medical Center. Dr. Corey Hopkins is a Professor of Medicinal Chemistry at the University of Nebraska College of Pharmacy. Fannin in-licensed 11h in 2020. Fannin was shortly thereafter awarded an SBIR Phase 1 grant for the development of 11h for opioid use disorder. Since then, 11h has shown evidence in a wide range of disease states and has begun gearing up for IND-enabling studies.
Mission Statement
To address neuroinflammation, the central component in numerous disease states, and promote neuroprotection and a healthy life starting with a healthier brain.
What We Do
Fannin primarily in-licenses promising, early-stage therapeutic and medical device technologies from leading academic investigators in the Texas Medical Center and on a national stage. Fannin develops and de-risks these technologies via preclinical work and engineering up through early clinical trials. Additionally, Fannin builds the business model and use case, resulting in strategic partnerships or acquisitions.
Our Model
Fannin operates in a capital-efficient way; we utilize a shared management team of experienced entrepreneurs, scientists, and engineers to collectively develop and operate our portfolio technologies. Although Fannin has access to investor capital, Fannin emphasizes de-risking technologies through non-dilutive funding as much as possible.
